Dr. Prince is a seasoned physician and healthcare entrepreneur with over 40 years of clinical experience in Pediatric Emergency Medicine. As Medical Director and founder of Children’s Emergency Services, Inc.—the first and only fully private pediatric emergency practice in the U.S.—he led a team that treated nearly two million patients. Dr. Prince has served as faculty at Wright State University School of Medicine and pioneered the nation’s first pediatric urgent care center.

In addition to his clinical leadership, Dr. Prince is a proven innovator and executive, having founded multiple healthcare and business ventures, including Blue Ribbon Billing Company and Prince Biotech. As the current CEO of Prince Biotech and former CEO and board member of BioIncept, he brings deep expertise in medical innovation, business development, and strategic leadership to the biotechnology space.

Brian Huber is an accomplished biopharmaceutical executive with more than 30 years of leadership experience spanning drug discovery, clinical development, venture investment, and strategic operations. As Chief Operating Officer of Prince Biotech, he draws on a career that includes senior roles in both public and private companies—among them CEO of Shionogi/GW Pharmaceutical Inc., CEO of Cancer Advances, and CSO/COO positions at Carolina Longevity Institute, Cato BioVentures, and Adherex Pharmaceuticals.

Brian has led programs from early discovery through global registration, contributing to six NDA approvals and numerous INDs across oncology, virology, rare diseases, and metabolic disorders. His decade at Quintiles/IQVIA as SVP/Managing Director in Drug Development Partnerships and his tenure as VP at ICON PLC honed his expertise in risk-based clinical development, value inflection strategies, and operational excellence. He has also served as a strategic advisor to venture capital and private equity firms, guiding portfolio companies to maximize clinical and commercial value.

Board-certified in Clinical Pharmacology, Brian holds academic appointments at Duke University Medical Center, The George Washington University Medical Center, and Durham Technical Community College. His blend of scientific rigor, operational leadership, and investment insight positions him to drive Prince Biotech’s mission of advancing transformative therapies to patients worldwide.

Dr. Barnea is the pioneering scientist behind the discovery of PreImplantation Factor (PIF), a naturally occurring peptide secreted by embryos that plays a critical role in immune regulation and tolerance. As Chief Scientific Officer and co-founder of BioIncept, LLC, a clinical-stage biotechnology company, Dr. Barnea leads the translation of this discovery into therapeutic and diagnostic innovations for fertility, immune modulation, and regenerative medicine.

An internationally recognized authority on early pregnancy, Dr. Barnea has authored over 180 peer-reviewed publications and book chapters and edited four specialty textbooks. He founded the Society for the Investigation of Early Pregnancy (SIEP) in 1990 and has chaired five global conferences on the subject. His leadership has fostered a prestigious network of collaborators from top-tier institutions, all working to unlock the full potential of PIF.

Dr. Barnea earned his medical degree cum laude from the University of Milan and completed his residency and fellowship training at the University of Pennsylvania, McGill University, and Yale University, where he also served as Chief Resident and Assistant Professor. Board certified in both OB-GYN and Reproductive Endocrinology, he brings decades of clinical insight to his scientific work. His contributions to medicine have been recognized with honors including the Elkeles Prize for Scientist of the Year in Medicine and the Bratanov Medal for advancements in immunology.

With over 35 years of executive leadership and governance experience, Steve Sloate brings a distinguished track record of driving transformation across academic health science centers, health systems, and entrepreneurial ventures. His expertise spans strategy, performance acceleration, business development, and turnaround management in both public and private sectors.

Mr. Sloate has held senior leadership roles at institutions such as Duke University Medical Center and the University of Florida’s Shands HealthCare System, where he led strategic planning, marketing, and system-wide transformation initiatives. He has also served as Executive Vice President and minority owner of Cambio Health Solutions, where he led national turnaround efforts for distressed nonprofit healthcare institutions.

A pioneer in public-private partnerships, Mr. Sloate has developed governance and financial models for new medical schools and academic health science centers, including initiatives with the University of Miami, Florida Atlantic University, and the University of South Carolina. His work has consistently focused on aligning diverse stakeholders—from governors and legislators to university presidents and healthcare executives—around shared strategic goals.

In the private sector, Mr. Sloate has served as President, EVP, and board member for multiple venture-backed companies at the intersection of healthcare, software, and intellectual property commercialization. His areas of expertise include mergers and acquisitions, capital formation, strategic communications, and commercialization of innovative solutions to complex challenges.

Mr. Sloate holds a B.S. in Business Administration and an MBA from the University of Florida, with additional graduate training in Health and Hospital Administration. He has held graduate school academic appointments at UNC-Chapel Hill, Duke University, and Kent State University, and is a frequent speaker on the future of healthcare, strategy, and innovation.

With over 40 years of executive leadership and governance experience, Jay Levy is a seasoned financial strategist and operational innovator. In addition to Prince Biotech, he serves as CFO of OptiPulse Inc., a pioneer in disruptive optical wireless communication.

Throughout his career, Jay has led transformative initiatives in strategy, business development, mergers and acquisitions, and turnaround management. He was instrumental in the development and global deployment of CIRRUS, the first international ATM interchange network, and held the role of Senior Vice President at MasterCard International, where he oversaw a global systems development team managing 400 concurrent projects across three continents.

Jay’s expertise extends to technology transfer and strategic partnerships, having advised organizations across healthcare, nonprofit, construction, and retail sectors. His consulting work includes building complex business models that drive operational and financial performance, and implementing systems that ensure robust financial controls for both startups and mature enterprises.

As a lecturer at the University of North Carolina at Chapel Hill’s Gillings School of Global Public Health, Jay has developed simulation environments and business models that enhance strategic thinking in healthcare and commercial development.
He holds a degree in Finance from Indiana University.

Aaron Prince brings a dynamic blend of operational leadership, strategic planning, and cross-sector experience to his role at Prince Biotech. As Director of Operations, he oversees all administrative functions and drives the execution of strategic initiatives that support the company’s mission to advance biotech innovation.

Aaron has played a pivotal role in shaping the company’s identity, leading the development and rollout of its initial branding. He is also responsible for grant writing and compliance, having successfully prepared and managed NIH/NIAID grant applications, disbursements, and reporting. His financial oversight ensures accountability and transparency across all grant-related activities.

With a strong focus on technology solutions, Aaron manages data systems, scheduling, and document production to streamline operations. His background includes leadership roles in real estate investment and leasing, where he negotiated over $1 billion in commercial leases and directed multimillion-dollar property acquisitions and renovations.

Aaron holds a Bachelor of Arts in Ecology and Evolutionary Biology from Princeton University, where he also captained the NCAA Division I baseball team.